The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
News|Articles|September 30, 2026
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
Author(s)Targeted Oncology Staff
Fact checked by: Sabrina Serani
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
The FDA's September 2026 oncology activity included accelerated approvals for camizestrant (Etcamah) in ESR1-mutant breast cancer and sevabertinib (Hyrnuo) in treatment-naive HER2-mutant non–small cell lung cancer (NSCLC), new approvals in cholangiocarcinoma, renal cell carcinoma (RCC), and neuroendocrine tumors, and the withdrawal of an application for ifinatamab deruxtecan (I-DXd) in small cell lung cancer.¹
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Published findings from the ASPEN-06 trial of evorpacept in previously treated HER2+ gastric cancers included exploratory analyses suggesting CD47 is a predictive biomarker for benefit with the targeted agent.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
The FDA communicated that the phase 2 IDeate-Lung01 results were not sufficient for an accelerated approval of I-DXd in small cell lung cancer.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
Advertisement
Advertisement